Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: A single institution phase II study

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3441-3444

  Ralli, Maria ^a,b   Tourkantonis, Ioannis ^a   Makrilia, Nektaria ^a   Gkini, Eleni ^a   Kotteas, Elias ^a   Gkiozos, Ioannis ^a   Katirtzoglou, Nikolaos ^a   Syrigos, Kostas ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Docetaxel; First line chemotherapy; Gemcitabine; Mesothelioma

Indexed keywords

DOCETAXEL; GEMCITABINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 68549106008     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Porret E, Madelaine J, Galateau-Sallé F, Bergot E and Zalcman G: Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007-an update. Rev Mal Pespir 24(8 Pt 2): 6S157-164, 2007 (in French).
2. Ellis P, Davies AM, Evans WK, Haynes A, Lloyd N and Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care: The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 1(6): 591-601, 2006.
3. British Thoracic Society Standards of Care Committee: BTS statement on malignant mesothelioma in the UK. Thorax 62(Suppl 2): ii1-ii1, 2007.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C and Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14): 2636-2644, 2003. (Pubitemid 46606305)
5. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G and European Organistaion for Research and Treatment of Cancer Lung Cancer Group and National Cancer Institute of Canada: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23(28): 6881-6889, 2005.
6. Lee CW, Murray N, Anderson H, Rao SC and Bishop W: Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review practice in British Columbia. Lung Cancer 64(3): 308-313, 2009. Epub 2008 Nov 11.
7. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH and Robinson BW: Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17(1): 25-30, 1999. (Pubitemid 29022374)
8. van Haarst JM, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ and van Meerbeeck JP: Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86(3): 342-345, 2002. (Pubitemid 34187648)
9. Nowak A, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW and Robinson BW: A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87(5): 491-496, 2002. (Pubitemid 35052715)
10. Utkan G, Büyükçelik A, Yalçin B, Akbulut H, Demirkazik A, Dinçol D, Onur H, Gören D, Mousa U, Senler FC and Içli F: Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung Cancer 53(3): 367-374, 2006. (Pubitemid 44192595)
11. Belani CP, Adak S, Aisner S, Stella PJ, Levitan N and Johnson DH: Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Group. Clin Lung Cancer 6(1): 43-47, 2004. (Pubitemid 39199285)
12. Kindler HL and van Meerbeeck JP: The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol 29(1): 70-76, 2002. (Pubitemid 34163537)
13. Syrigos KN, Karapanagiotou E, Charpidou A, Dilana K, Dannos I, Dionellis G, Rigopoulou A, Georgatou N and Roussos C: Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study. J Chemother 19(4): 438-443, 2007. (Pubitemid 47236524)
14. Syrigos KN, Konstantinou M, Sepsas E, Papamichales G, Loullias A, Belenis I, Skottis I, Charpidou A and Roussos C: Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study. Anticancer Res 27(4C): 2887-2892, 2007. (Pubitemid 47228016)
15. Syrigos KN, Dannos I, Dionellis G, Bofos I, Alamara C, Dimakou E, Stratakos G and Papiris S: Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study. Anticancer Res 25(5): 3489-3494, 2005. (Pubitemid 41105228)
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-247, 2009.
17. Plathow C, Klopp M, Thieke C, Herth F, Thomas A, Schmaehl A, Zuna I and Kauczor HU: Therapy response in malignant pleural mesothelioma role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT. Eur Radiol 18(8): 1635-1643, 2008.
18. Vogelzang NJ: Standard therapy for the treatment of malignant pleural mesothelioma. Lung Cancer 50(Suppl 1): S23-24, 2005.
19. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E and Crippa M: Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 67(12): 2984-2987, 1991.
20. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon JE 2nd, Aisner J, Ellison RR and Leone L: Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia group B. J Clin Oncol 11(8): 1559-1565, 1993.
21. Fizazi K, Doubre H, Le Chevalier T, Riviere A, Viala J, Daniel C, Robert L, Barthélemy P, Fandi A and Ruffié P: Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 21(2): 349-354, 2003. (Pubitemid 46606165)
22. Fennell DA, C Steele JP, Shamash J, Sheaff MT, Evans MT, Goonéwardene TI, Nystrom ML, Gower NH and Rudd RM: Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 47(2): 277-281, 2005. (Pubitemid 40089485)
23. Schutte W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscqkaeger B, Treutler D, Schneider CP and Bonner R: A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 4(5): 294-297, 2003. (Pubitemid 36546414)
24. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L and Procopio A: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193(4): 468-475, 2001. (Pubitemid 32266815)
25. Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L, Janne P, Guterz TL, Stadler WM and Vokes EE: A multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Proc Am Soc Clin Oncol 23: 625s, abstract 7019, 2005.